Vasculitis & polymyalgia rheumatica
Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry
Authors' conclusion
In this first multi-centre series of GCA from Turkey, we observed that only one-fifth of patients had relapses during a mean follow-up of 26 months, with 76.4% given a GC-sparing IS agent at diagnosis.
Study context
- Population
- Patients with giant cell arteritis (GCA) (ACR 1990 criteria) from tertiary rheumatology centres in TurkeyF/M: 196/134
- Participants
- 330 patients
- Outcome
- Real-life relapse rate (new manifestation or increased acute-phase response leading to GC dose change or new therapeutic agent)
Methodological detailsmulticentre, registry
- Multicentre
- Registry
Main finding
As reported in the abstract
Relapse · median 26.5 (6-190) months follow-up
Patients with relapse
49
18.8%
Observational data: associations, not effects.
Further findings
Glucocorticoids (GC) treatment stopped
- Patients in whom GC could be stopped
- 62 (23.8%)
Immunosuppressives as GC-sparing agents used
- Patients
- 252 (76.4%)
Safety
GC-related side effects
- Patients
- 64 (24.6%)
At least one Vasculitis Damage Index (VDI) damage item during follow-up
- Patients
- 141 (66.2%)
Original publication
Low relapse rate in patients with giant cell arteritis in a multi-centre retrospective Turkish Registry. Clin Exp Rheumatol. Published 29 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →